A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

Expanded access is no longer available for this treatment.
Sponsor:
Collaborator:
Pfizer
Information provided by:
ViiV Healthcare
ClinicalTrials.gov Identifier:
NCT00801515
First received: December 2, 2008
Last updated: July 21, 2011
Last verified: July 2011

December 2, 2008
July 21, 2011
August 2009
July 2011   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00801515 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

This is a compassionate study to provide continued access to maraviroc for only those subjects completing study A4001029 who are showing clinical benefit. Assessments of safety and tolerability of maraviroc when added to OBT will be continued.

Not Provided
Expanded Access
Phase 3
Not Provided
HIV
Drug: Maraviroc
150 mg twice per day
Other Name: Celsentri
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
No longer available
Not Provided
July 2011
July 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients having completed study A4001029 in Canada and still deriving clinical benefit.

Exclusion Criteria:

  • None
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00801515
A4001090
No
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ViiV Healthcare
Pfizer
Study Director: Pfizer CT.gov Call Center Pfizer
ViiV Healthcare
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP